Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01092611 | Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine | PHASE1 | COMPLETED | 190 | — | — | Mar 22, 2010 | May 19, 2014 | Mar 2, 2018 | 41 | United States, France +2 |
| Arm | Type | Description |
|---|---|---|
| Group A | OTHER | Subjects who were administered the GSK HIV vaccine 732462 in primary studies and who accepted to participate in this study |
| Group B | OTHER | Subjects who were administered placebo in primary studies and who accepted to participate in this study |
| Name | Type | Description |
|---|---|---|
| Blood collection | PROCEDURE | Once a year after Visit 1 (during a maximum of 4 years). The samples will only be taken in conjunction with, and at the same time as, planned routine blood testing using the same needle-stick. |
| GSK HIV vaccine 732462 | BIOLOGICAL | No vaccine will be administered during this long-term follow-up study. Vaccines were administered during the primary studies. |
Inclusion Criteria: All subjects must satisfy ALL the following criteria at study entry: * HIV-infected subject. * Previous participation in a study evaluating GSK HIV vaccine 732462. * Written informed consent obtained from the subject. Exclusion Criteria: The following criteria should be check...